Randox Laboratories has installed an RX modena in a COVID-19 hospital in India, at the Netaji Subhash Chandra Bose Medical College in Madhya Pradesh state.
Scientists from PrecisionLife have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients who had a severe response to SARS-CoV-2.
Una Health, a distributor of in vitro diagnostics (IVDs), and Fortress Diagnostics, a provider of IVDs, are partnering with the Department of Health & Social Care in the Real Time Assessment of Community Transmission (REACT) study into COVID-19.
HORIBA UK, Medical has published a white paper entitled ‘COVID-19 screening, prognosis and severity assessment with biomarkers for management of patients’. The paper provides a review of biomarkers that help in the assessment of COVID-19 severity.
Avacta Group has announced that the first Affimer-based rapid test strips to detect SARS-COV-2 spike protein have been evaluated by Avacta’s partners at Cytiva (formerly GE Healthcare Life Sciences) and show positive initial performance data.
The SARS-CoV-2 pandemic has placed unprecedented pressure on research and diagnostic laboratories to process more samples more quickly. INTEGRA Biosciences offers a range of pipetting systems designed to speed up PCR-based screening workflows.
Ploughshare Innovations, a Defence Science and Technology Laboratory (Dstl) spin-out firm, has funded the development of a revolutionary test that has the potential to predict whether coronavirus patients will develop sepsis before symptoms appear.
Bio-Rad provides a wide range of products for use in the support of COVID-19 diagnosis and confirmation, and offers a suite of molecular testing tools including Droplet Digital PCR (ddPCR) systems and the SARS-CoV-2 ddPCR test kit.
Infectivity assays carried out by the Avacta Group in collaboration with the Centre for Virus Research at the University of Glasgow show that the company’s Affimer reagents prevent infection of human cells by a SARS-CoV-2 model virus.
A Danish pipetting robot is automating coronavirus testing processes in European hospitals. The robot, called flowbot ONE, significantly reduces the time it takes for laboratories to produce results for patients potentially infected with SARS-CoV-2.
The SARS-CoV-2 pandemic has led to the development of novel RT-PCR-based tests to detect the virus. As the situation has progressed, serology tests are now needed to evaluate the immune response of patients, and assess immunity in the general public.
The ScheBo SARS-CoV-2 Quick is a combined immunochromatographic lateral-flow test for the simultaneous qualitative detection of SARS-CoV-2 IgM and IgG antibodies in whole blood, serum or plasma, with test results after 15 minutes.
Oxford Immunotec has released the T-SPOT Discovery SARS-CoV-2 test kit. This could make a significant contribution to development of a tool to manage the current pandemic, and help nations come out of lockdown faster, safer and in a controlled manner
Beckman Coulter’s Access SARS-CoV-2 IgG assay is now available in markets accepting the CE mark. The company has shipped tests to more than 400 hospitals, clinics and laboratories in the USA, and has begun shipping to customers globally.
An innovative method of monitoring treatment efficacy and recovery from COVID-19 has been unveiled by global diagnostics company Randox Laboratories. The test detects the presence of cytokines, and is performed on the company’s Biochip Technology.